



DAFTAR PUSTAKA

- Abbas, A.K., Lichtman, A.H. & Pillai, S. 2016. *Imunologi Dasar Abbas*. 5th ed. H. Kalim, ed. Singapura. pp: 27-54.
- Adejumo, O.A., Okaka, E.I., Okwuonu, C.G., Iyawe, I.O. & Odujoko, O.O. 2016. Serum C-reactive protein levels in pre-dialysis chronic kidney disease patients in southern Nigeria. *Ghana Med J*, 50(1): 31–38.
- Alves, F.C., Sun, J., Qureshi, A.R., Dai, L., Snaedal, S., Bárány, P., Heimbürger, O., Lindholm, B. & Stenvinkel, P. 2018. The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease. *PLoS ONE*, 13(1): 1–15.
- Arya, A., Aggarwal, S. & Yadav, H.N. 2010. Review Article Pathogenesis of Diabetic Nephropathy. *Int J Pharm Pharm Sci*, 2(4): 24–29.
- Betriu, A., Martinez-Alonso, M., Arcidiacono, M.V., Cannata-Andia, J., Pascual, J., Valdivielso, J.M. & Fernández, E. 2014. Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: The NEFRONA study. *Nephrol Dial Transplant*, 29(7): 1415–1422.
- Cazzavillan, S., Ratanarat, R., Segala, C., Corradi, V., De Cal, M., Cruz, D., Ocampo, C., Polanco, N., Rassa, M., Levin, N. & Ronco, C. 2006. Inflammation and subclinical infection in chronic kidney disease: A molecular approach. *Blood Purif*, 25(1): 69–76.
- Cohen, G. & Hörl, W.H. 2012. Immune Dysfunction in Uremia—An Update. : 962–990.
- Creager, M.A. & Libby, P. 2015. Diabetes and Atherosclerosis. , 287(19).
- Dahlan, S. 2014. *Statistik untuk Kedokteran dan Kesehatan*. 6th ed. Jakarta: Epidemiologi Indonesia.
- Daugidas, J.T. 2015. *Complications during haemodialysis*. 5th ed. US.
- Edwards, D.G. & Martens, C.R. 2011. Peripheral vascular dysfunction in chronic kidney disease. *Cardiol Res Pract*, 1(1).
- El-Sheikh, M. & El-Ghazaly, G. 2016. Assessment of hemodialysis adequacy in patients with chronic kidney disease in the hemodialysis unit at Tanta University Hospital in Egypt. *Indian J Nephrol*, 26(6): 398–404.
- Fichtlscherer, S., Breuer, S., Heeschen, C., Dimmeler, S. & Zeiher, A.M. 2004. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. *J Am Coll Cardiol*, 44(1): 44–49. <http://dx.doi.org/10.1016/j.jacc.2004.02.054>.
- Friedman, A.N. & Fadem, S.Z. 2010. Reassessment of albumin as a nutritional marker in kidney disease. *J Am Soc Nephrol*, 21(2): 223–230.
- Gohel, M.G. & Chacko, A.N. 2013. Serum GGT activity and hsCRP level in patients with type 2 diabetes mellitus with good and poor glycemic control: An evidence linking oxidative stress, inflammation and glycemic control. *J Diabetes Metab Disord*, 12(1): 1–8.
- Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., Callaghan, A.O., Lasserson, D.S. & Hobbs, F.D.R. 2016. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. : 1–18.
- hsCRP Instruction sheet. 2012. Cardiac C-Reactive Protein (Latex) High Sensitive.



, 8: 1–4.

- Hwang, J.C., Jiang, M.Y., Lu, Y.H. & Wang, C.T. 2015. Precedent fluctuation of serum hs-CRP to albumin ratios and mortality risk of clinically stable hemodialysis patients. *PLoS ONE*, 10(3): 1–14.
- Ilmiah, M., Anniwati, L. & Soehartini, S. 2018. Metode Bromcresol Green (Bcg) Dan Bromcresol Purple (Bcp) Pada Sirosis Hati Yang Mendapat Infus Albumin. *Indones J Clin Pathol Med Lab*, 20(2): 73.
- Irndt, M.A.G., Ester, U.R.S., Ester, M.A.S., Eman, E.R.I.K.D. & Lrich, C.H.U. 2001. The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. , 60: 2385–2391.
- Jialal, I. & Devaraj, S. 2001. The value of the high-sensitivity C-reactive protein assay as a risk marker. *Am J Clin Pathol*, 116(Suppl 1): S108–S115. <http://www.ncbi.nlm.nih.gov/pubmed/11993695>.
- Jofré, R., Rodriguez-Benitez, P., López-Gómez, J.M. & Pérez-Garcia, R. 2006. Inflammatory syndrome in patients on hemodialysis. *J Am Soc Nephrol*, 17(SUPPL. 3): 274–280.
- Kaplan, M.M. 2013. Primary Biliary Cirrhosis. *Encycl Biol Chem: Second Ed*, 17: 561–565.
- Kaysen, G.A. 1998. Biological basis of hypoalbuminemia in ESRD. *J Am Soc Nephrol*, 9(12): 2368–2376.
- KDOQI. 2002. Part 4. Definition and Classification of Stages of Chronic Kidney Disease. *Am J Kidney Dis*, 39(2): S46–S75.
- Khan, Y.H., Mallhi, T.H., Sarriff, A. & Amer Hayat Khan, Amer Hayat Tanveer, N. 2018. Prevalence of Chronic Kidney Disease in Asia : A Systematic Review of Population-Based Studies. , 28(12): 960–966.
- Kiechle, F.L. 2007. Clinical pathology and revenue. *J Clin Ligand Assay*, 29(4): 204–205.
- Kohlová, M., Amorim, C.G., Araújo, A., Santos-Silva, A., Solich, P. & Montenegro, M.C.B.S.M. 2019. The biocompatibility and bioactivity of hemodialysis membranes: their impact in end-stage renal disease. *J Artifl Organs*, 22(1): 14–28. <http://dx.doi.org/10.1007/s10047-018-1059-9>.
- Kronenberg, F., Lingenhel, A., Neyer, U., Lhotta, K., König, P., Auinger, M., Wiesholzer, M., Andersson, H. & Dieplinger, H. 2003. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. *Kidney Int, Suppl*, 63(84): 113–116.
- Ku, E., Lee, B.J., Wei, J. & Weir, M.R. 2019. Hypertension in CKD: Core Curriculum 2019. *A J Kidney Dis*, 74(1): 120–131. <https://doi.org/10.1053/j.ajkd.2018.12.044>.
- Lestariningsih, L., Hardisaputro, S., Nurani, A., Santosa, D. & Santoso, G. 2019. High sensitivity C-reactive protein as a predictive of intima-media thickness in patients with end-stage renal disease on regular hemodialysis. *Int J Gen Med*, 12: 219–224.
- Levey, A.S., Atkins, R., Coresh, J., Cohen, E.P., Collins, A.J., Eckardt, K.U., Nahas, M.E., Jaber, B.L., Jadoul, M., Levin, A., Powe, N.R., Rossert, J., Wheeler, D.C., Lameire, N. & Eknoyan, G. 2007. Chronic kidney disease as a global public health problem: Approaches and initiatives - A position



- statement from Kidney Disease Improving Global Outcomes. *Kidney Int*, 72(3): 247–259. <http://dx.doi.org/10.1038/sj.ki.5002343>.
- Libra, M., Signorelli, S.S., Bevelacqua, Y., Navolanic, P.M., Bevelacqua, V., Polesel, J., Talamini, R., Stivala, F., Mazzarino, M.C. & Malaponte, G. 2006. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. *J Clin Pathol*, 59(2): 211–215.
- Matovinović, M.S. 2009. 1. Pathophysiology and Classification of Kidney Diseases. *Ejifcc*, 20(1): 2–11. <http://www.ncbi.nlm.nih.gov/pubmed/27683321> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4975264>.
- Meier, P., Golshayan, D., Blanc, E., Pascual, M. & Burnier, M. 2009. Oxidized LDL modulates apoptosis of regulatory T cells in patients with ESRD. *J Am Soc Nephrol*, 20(6): 1368–1384.
- Menon, V., Greene, T., Wang, X., Pereira, A.A., Marcovina, S.M., Beck, G.J., Kusek, J.W., Collins, A.J., Levey, A.S. & Sarnak, M.J. 2005. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. *Kidney Int*, 68(2): 766–772.
- Merlot, A.M., Kalinowski, D.S. & Richardson, D.R. 2014. Unraveling the mysteries of serum albumin-more than just a serum protein. *Front Physiol*, 5 AUG(August): 1–7.
- Moussa, S.A. 2008. Oxidative stress in Diabetes Mellitus. , 18(3): 225–236.
- Murdaca, G., Spanò, F., Cagnati, P. & Puppo, F. 2013. Free radicals and endothelial dysfunction: Potential positive effects of TNF- α inhibitors. *Redox Rep*, 18(3): 95–99.
- de Mutsert, R., Grootendorst, D.C., Indemans, F., Boeschoten, E.W., Krediet, R.T. & Dekker, F.W. 2009. Association Between Serum Albumin and Mortality in Dialysis Patients Is Partly Explained by Inflammation, and Not by Malnutrition. *J Ren Nutr*, 19(2): 127–135.
- Nicholson, J.P., Wolmarans, M.R. & Park, G.R. 2000. Review Article The role of albumin in critical illness. *Br J Anaesth*, 85(4): 599–610.
- NKF-KDIGO. 2012. On translation of LD, IL and SFC given according to IEC-61131 for hardware synthesis of reconfigurable logic controller. *IFAC Proc Vol (IFAC-PapersOnline)*, 19(1): 4477–4483.
- Oberg, B.P., McMenamin, E., Lucas, F.L., McMonagle, E., Morrow, J., Ikizler, T.A. & Himmelfarb, J. 2004. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. *Kidney Int*, 65(3): 1009–1016.
- Pasceri, V., Willerson, J.T. & Yeh, E.T.H. 2000. Direct proinflammatory effect of C-reactive protein on human endothelial cells. *Circulation*, 102(18): 2165–2168.
- Pauletto, P. & Rattazzi, M. 2006. Inflammation and hypertension: The search for a link. *Nephrol Dial Transplant*, 21(4): 850–853.
- Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon, R.O., Criqui, M., Fadl, Y.Y., Fortmann, S.P., Hong, Y., Myers, G.L., Rifai, N., Smith, S.C., Taubert, K., Tracy, R.P. & Vinicor, F. 2003. Markers of



- inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. *Circulation*, 107(3): 499–511.
- Pepys, M.B. & Hirschfield, G.M. 2003. C-reactive protein: a critical update. *J Clin Invest*, 112(2): 299–299.
- PERNEFRI. 2017. 10 th Report Of Indonesian Renal Registry 2017 10 th Report Of Indonesian Renal Registry 2017.
- Rani, T. 2001. Pengaruh Penggunaan Ginjal Buatan (Dializer) Baru dan Berulang Terhadap Kadar Albumin Serum.
- Rathore, V. 2018. Risk Factors of Acute Myocardial Infarction: A Review. *Eurasian J Med Investig*, 2(1): 1–7.
- Ren, T., Xiong, J., Liu, G., Wang, S., Tan, Z., Fu, B., Zhang, R., Liao, X., Wang, Q. & Guo, Z. 2019. Imbalance of Th22/Treg cells causes microinflammation in uremic patients undergoing hemodialysis. *Biosci Rep*, 39(10): 1–10.
- Reynard, M.P., Turner, D. & Navarrete, C. V. 2000. Allele frequencies of polymorphisms of the tumour necrosis factor- α , interleukin-10, interferon- γ and interleukin-2 genes in a North European Caucasoid group from the UK. *Eur J Immunogenet*, 27(4): 241–249.
- Ricos, C., Alvarez, V., Garcia-Lario, J.V., A, H., Jimenez, C.-V., Minchinela, J., Perich, C. & Simon, M. 2014. Desirable Specifications for Total Error , Imprecision , and Bias , derived from intra- and inter-individual biologic variation. *Scand J Clin Lab Invest*, 59: 1–13.
- Ridker, P.M. 2003. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. *Circulation*, 107(3): 363–369.
- Riskesdas. 2018. HASIL UTAMA RISKESDAS 2018.
- Roche Diagnostics. 2011. Albumin Gen.2 • : 4–6.
- Sastroasmoro, S. 2014. Dasar-dasar Metodologi Penelitian Klinis. In *Sagung Seto*. Jakarta: 13–29.
- Seyrek, N., Karayaylali, I., Balal, M., Paydas, S., Aikimbaev, K., Cetiner, S. & Seydaoglu, G. 2005. Is there any relationship between serum levels of interleukin-10 and atherosclerosis in hemodialysis patients ? , (April 2004): 405–410.
- Shao, Y., Cheng, Z., Li, X., Chernaya, V., Wang, H. & Yang, X.F. 2014. Immunosuppressive/anti-inflammatory cytokines directly and indirectly inhibit endothelial dysfunction-A novel mechanism for maintaining vascular function. *J Hematol Oncol*, 7(1): 1–14.
- Sinha, S., Kar, K., Soren, M. & Dasgupta, A. 2014. hsCRP in pre-hypertension and hypertension: a prospective study in Southern Asian region. *Int J Res Med Sci*, 2(4): 1402.
- Stenvinkel, P. 2001. Endothelial dysfunction and inflammation - Is there a link? *Nephrol Dial Transplant*, 16(10): 1968–1971.
- Stenvinkel, P. & Lindholm, B. 2005. C-Reactive protein in end-stage renal disease: Are there reasons to measure it? *Blood Purif*, 23(1): 72–78.
- Stratton, R.J., Bircher, G., Fouque, D., Stenvinkel, P., De Mutsert, R., Engfer, M. & Elia, M. 2005. Multinutrient oral supplements and tube feeding in



- maintenance dialysis: A systematic review and meta-analysis. *Am J Kidney Dis*, 46(3): 387–405.
- Suhardjono, S. 2015. End-stage renal disease in Indonesia: Treatment development. (December).
- Sumanth, B. & Shobharani, B. 2015. Comparative Study of Hscrp in Chronic Kidney Disease. *IOSR J Pharm*, 5(7): 8–12.
- Taverna, M., Marie, A.L., Mira, J.P. & Guidet, B. 2013. Specific antioxidant properties of human serum albumin. *Ann Intensive Care*, 3(1): 1–7. *Annals of Intensive Care*.
- USRDS. 2017. Chapter 3 : Morbidity and Mortality in Patients with CKD. , 1: 47–76.
- Venugopal, S.K., Devaraj, S., Yuhanna, I., Shaul, P. & Jialal, I. 2002. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. *Circulation*, 106(12): 1439–1441.
- Verma, S., Badiwala, M. V., Weisel, R.D., Li, S.H., Wang, C.H., Fedak, P.W.M., Li, R.K., Mickle, D.A.G., Wahba, A., Milano, C.A., Vinten-Johansen, J. & Woo, Y.J. 2003. C-reactive protein activates the nuclear factor- κ B signal transduction pathway in saphenous vein endothelial cells: Implications for atherosclerosis and restenosis. *J Thorac Cardiovasc Surg*, 126(6): 1886–1891.
- Yeun, J.Y. & Kaysen, G.A. 1998. Factors influencing serum albumin in dialysis patients. *Am J Kidney Dis : the official journal of the National Kidney Foundation*, 32(6 Suppl 4): 118–125.
- Yusop, N.B., Mun, C.Y., Shariff, Z.M. & Huat, C. 2013. Factors Associated with Quality of Life among Hemodialysis Patients in Malaysia. , 8(12): 1–11.
- Zhang, C. 2008. The role of inflammatory cytokines in endothelial dysfunction. *Basic Res Cardiol*, 103(5): 398–406.